- Previous Close
14.65 - Open
14.34 - Bid 14.01 x 800
- Ask 14.01 x 1100
- Day's Range
13.76 - 14.57 - 52 Week Range
8.52 - 18.80 - Volume
4,828,571 - Avg. Volume
5,342,801 - Market Cap (intraday)
7.108B - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-2.55 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.23
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
www.elanco.com9,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ELAN
View More
Performance Overview: ELAN
Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELAN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELAN
View MoreValuation Measures
Market Cap
7.24B
Enterprise Value
12.50B
Trailing P/E
--
Forward P/E
13.95
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.61
Price/Book (mrq)
1.22
Enterprise Value/Revenue
2.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.94%
Return on Assets (ttm)
1.30%
Return on Equity (ttm)
-18.78%
Revenue (ttm)
4.49B
Net Income Avi to Common (ttm)
-1.26B
Diluted EPS (ttm)
-2.55
Balance Sheet and Cash Flow
Total Cash (mrq)
416M
Total Debt/Equity (mrq)
95.52%
Levered Free Cash Flow (ttm)
175.12M
Research Analysis: ELAN
View MoreCompany Insights: ELAN
ELAN does not have Company Insights
Research Reports: ELAN
View MoreHOLD on weak near-term outlook
Elanco Animal Health, based in Greenfield, Indiana, provides products for both companion and food animals. It became the second-largest animal health company in the world following its acquisition of Bayer's animal health business. Founded in 1954 as part of Eli Lilly, it was spun off from Lilly through an IPO on September 24, 2018. Elanco sells its products in more than 90 countries and has a market capitalization of approximately $7.5 billion. The company has approximately 9,300 full-time employees.
RatingPrice TargetStocks are higher across the board, getting a boost from a positive revision
Stocks are higher across the board, getting a boost from a positive revision to 2Q US GDP. The new number shows that the economy grew at a 3.0% rate for the quarter. The Nasdaq is higher despite a poor reception to Nvidia (NVDA) earnings out after-the-bell last night.
FDA plans box warning on Zenrelia
Elanco Animal Health, based in Greenfield, Indiana, provides products for both companion and food animals. It became the second-largest animal health company in the world following its acquisition of Bayer's animal health business. Founded in 1954 as part of Eli Lilly, it was spun off from Lilly through an IPO on September 24, 2018. Elanco sells its products in more than 90 countries and has a market capitalization of approximately $6.6 billion. The company has approximately 9,300 full-time employees.
RatingPrice TargetThe overall stock market had another very good day on July 16 -- but, once
The overall stock market had another very good day on July 16 -- but, once again, it was because of the now-loved (at least for now) little guys. To put this into perspective, the total market cap of the Russell 2000 (IWM) is said to be only as large as one of the multiple $3 trillion market-cap stocks in the 'Magnificent 7.' But let's not spoil the party as stocks are posting some historical returns on massive trading volume. Over the past five days, IWM has soared 11.5%. Excluding the comeback from the pandemic, the index has logged the greatest five-day period since October 2011. Before that, you have to go back to the initial rally after the March 2009 bear-market low to find such a move. The IWM is now only nine points (or about 4%) from its November 8, 2021, all-time high. It has completed a massive 31-month consolidation and, as they say, the larger the base, the higher in space. Over the past four days, IWM volume has exploded as investors have piled into the small-cap trade. The four-day volume totaled 227.4 million shares or 56.9 mln./day. The 50-day average for volume is 26.5 mln. shares and the 200-day average is 36 mln. shares. This is the largest cluster of volume during an IWM rally since December. Almost always, large clusters of huge volume happen during corrections and bear markets and many times represent downside capitulation. Market breadth has obviously been strong, with the four-day NYSE advances-declines hitting +1,004. This is a short-term breadth thrust and is usually associated with the beginning of an advance.